By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – RainDance Technologies has closed a Series D financing round that has raised $37.5 million, the Lexington, Mass.-based firm said today.

RainDance said that it will use the funds to develop new applications for its commercial targeted sequencing and sequence enrichment solution in the medical genetics and research markets. It also plans to grow its global sales and support infrastructure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.